ResMed Inc. (NYSE:RMD) Director John P. Wareham sold 25,934 shares of the business’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $102.25, for a total transaction of $2,651,751.50. Following the completion of the transaction, the director now directly owns 38,934 shares of the company’s stock, valued at approximately $3,981,001.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
ResMed Inc. (NYSE RMD) traded up $0.32 on Monday, reaching $103.12. 277,838 shares of the company’s stock traded hands, compared to its average volume of 857,931. ResMed Inc. has a 12 month low of $66.18 and a 12 month high of $104.78. The stock has a market capitalization of $14,692.91, a P/E ratio of 51.50, a P/E/G ratio of 2.37 and a beta of 0.79.
ResMed (NYSE:RMD) last released its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.22. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The company had revenue of $601.27 million during the quarter, compared to the consensus estimate of $583.77 million. During the same period in the previous year, the firm earned $0.73 earnings per share. ResMed’s revenue for the quarter was up 13.4% on a year-over-year basis. sell-side analysts anticipate that ResMed Inc. will post 3.34 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in RMD. Cubist Systematic Strategies LLC purchased a new position in shares of ResMed in the third quarter valued at $113,000. YorkBridge Wealth Partners LLC boosted its stake in ResMed by 4.9% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 69 shares during the last quarter. Toronto Dominion Bank boosted its stake in ResMed by 12.8% during the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 197 shares during the last quarter. Commerzbank Aktiengesellschaft FI bought a new position in ResMed during the 4th quarter valued at $206,000. Finally, BB&T Investment Services Inc. bought a new position in ResMed during the 2nd quarter valued at $214,000. Institutional investors and hedge funds own 61.83% of the company’s stock.
RMD has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of ResMed from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Northland Securities reaffirmed a “sell” rating and set a $55.00 price target on shares of ResMed in a research report on Friday, October 27th. BMO Capital Markets upped their price target on shares of ResMed to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, January 23rd. Macquarie lowered shares of ResMed from a “neutral” rating to a “sell” rating in a research report on Tuesday, January 23rd. Finally, Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a research report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. ResMed currently has a consensus rating of “Hold” and an average price target of $71.71.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/29/john-p-wareham-sells-25934-shares-of-resmed-inc-rmd-stock.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.